Evaluation and Management of Peripheral Nerve Sheath Tumors

Diagnostic Evaluation

• The optimal management of peripheral nerve sheath tumors requires an integrated diagnostic approach combining histopathologic, immunohistochemical, and molecular features to guide appropriate treatment decisions and improve patient outcomes 1, 2, 3
• Patients with suspected PNSTs should undergo evaluation by a specialized multidisciplinary team, ideally at a dedicated neurofibromatosis clinic, as this approach significantly reduces morbidity and mortality 4
• FDG-PET or diffusion-weighted MRI should be considered for lesions with concerning features to identify areas of increased metabolic activity or decreased apparent diffusion coefficient (ADC) 1, 3
• For clinically or radiologically suspicious lesions, a standardized biopsy approach is recommended, including the use of 14-18G biopsy needles and obtaining a minimum of 6 core biopsies if safe and feasible 3, 5
• Core biopsies should be divided into multiple blocks with no more than 2 core biopsies per block to minimize tissue depletion 2
• Histologic evaluation should be performed by a subspecialized pathologist, assessing features such as cytologic atypia, loss of neurofibromatous architecture, hypercellularity, mitotic count, and presence of necrosis 1, 2, 3, 7
• Immunohistochemical stains should be performed to assess SOX10 and S100 expression, CD34, p16 expression, H3K27me3, and p53 7, 8
• Molecular profiling is recommended for all clinically or radiologically worrisome noncutaneous lesions in patients with NF1, assessing key molecular features such as CDKN2A/B inactivation, SUZ12, EED, or TP53 inactivating mutations, and significant aneuploidy 7, 8, 9

Management Approach

• Atypical Neurofibromatous Neoplasm of Uncertain Biologic Potential (ANNUBP) is defined by the presence of at least 2 of the following features: cytologic atypia, loss of neurofibroma architecture, hypercellularity, and mitotic count >1/50 high-power fields but <3/10 high-power fields 2, 9
• Complete surgical resection is recommended for ANNUBP when feasible, with close surveillance due to uncertain biologic potential 8

Surveillance and Follow-up

• Annual general medical evaluation is recommended for patients with NF1, including assessment for signs/symptoms of MPNST, evaluation for pheochromocytoma, screening for neuropathy, assessment for depression and chronic pain, blood pressure measurement, and clinical evaluation for scoliosis 1, 4
• For women with NF1, annual mammogram starting at age 30 and consideration of breast MRI with contrast between ages 30-50 is recommended 4

Special Considerations

• The risk of NF1-associated MPNST increases with age: 8.5% by age 30, 12.3% by age 50, and 15.8% by age 85 4
• Life expectancy in NF1 is reduced by 8-15 years compared to the general population, primarily due to malignant neoplasms and cardiovascular causes 4
• Pregnant women with NF1 should be referred to a high-risk obstetrician and educated about the 50% offspring recurrence risk 4